CRISPR Therapeutics AG (CRSP)
Chart Events
Performance Outlook
| Previous Close | 52.23 |
| Open | 52.27 |
| Bid | 51.49 x 1100 |
| Ask | 51.63 x 4000 |
| Day's Range | 50.50 - 53.14 |
| 52 Week Range | 42.51 - 169.76 |
| Volume | |
| Avg. Volume | 1,452,731 |
| Market Cap | 4.003B |
| Beta (5Y Monthly) | 2.01 |
| PE Ratio (TTM) | 11.00 |
| EPS (TTM) | 4.70 |
| Earnings Date | May 09, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 121.86 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CRSP
Related Research
- CRISPR Therapeutics AGAnalyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.RatingFair ValueEconomic Moat6 days agoMorningstar
- Motley Fool
Why Editas Medicine's Shares Fell 28.9% This Week
Shares of Editas Medicine (NASDAQ: EDIT), a genome editing biotech company that uses CRISPR/Cas9 and CRISPR/Cas12a genome editing systems to develop therapies, saw its shares plummet 28.9% this week, according to data from S&P Global Market Intelligence. Editas' shares have steadily fallen this year, but it is hardly alone among gene-editing companies. Intellia Therapeutics is down more than 63% so far this year while CRISPR Therapeutics has seen its shares drop more than 38%.
- Motley Fool
2 Stocks With 75% to 183% Upside, According to Wall Street
Let's look at two stocks that boast significant upside potential, going by average price targets set by analysts on the street: Moderna (NASDAQ: MRNA) and CRISPR Therapeutics (NASDAQ: CRSP). Biotech giant Moderna fell along with the broader market in recent months. Moderna currently generates revenue from just one product: its coronavirus vaccine.
- Investor's Business Daily
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.
